uploads/2018/10/Chart-02-7-1.jpg

Allergan’s Q3 2018 Estimates: Revenue Decline Expected

By

Updated

Allergan’s Q3 2018 revenue estimates

Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decrease 3.8% to $3.88 billion. Allergan has classified its business operations into three business segments:

  • US Specialized Therapeutics
  • US General Medicine
  • International

The above graph compares Allergan’s revenues since the first quarter of 2017 and provides the estimate for the third quarter of 2018.

Article continues below advertisement

Revenue performance

Allergan’s revenue estimates for each of its business segments for the third quarter are as follows:

  • The US Specialized Therapeutics segment includes revenues from eye care products, medical dermatology products, medical aesthetic products, neuroscience products, and urology products. The segment is expected to report revenue growth in the third quarter, driven by strong sales of Botox, Kybella, Ozurdex, Restasis, and a few other products.
  • The US General Medicine segment includes revenues from anti-infective products, central nervous system products, gastroenterology products, women’s health products, and established brands. Lower sales of Namenda products are expected to drive the decline in revenues.
  • The International segment includes revenues from sales of general medicine and specialized products in international markets, excluding the United States. The segment is expected to report revenue growth following strong sales of Botox, eye care products, and fillers across the global markets.

The VanEck Vectors Biotech ETF (BBH) holds 5.2% of its total investments in Allergan (AGN), 8.5% in Amgen (AMGN), 7.1% in Gilead Science (GILD), and 5% in BioMarin Pharmaceutical (BMRN).

Advertisement

More From Market Realist